Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor.

Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-

Nomograms* ; Sarcoma*; Humans ; Area Under Curve ; Calibration ; Clinical Decision-Making ; SEER Program

Background: Malignant myofibroblastic tumors are a rare group of soft tissue sarcomas, for which a prognosis prediction model is lacking. Based on the Surveillance, Epidemiology, and End Results (SEER) database and cases from Nanjing Drum Tower Hospital, the current study constructed and validated a nomogram to assess overall survival of patients with malignant myofibroblastic tumors.
Methods: Data of patients with myofibroblastic tumors diagnosed between 2000 and 2018 were extracted from the SEER database. Similarly, data of patients with myofibroblastic tumor in Nanjing Drum Tower Hospital between May 2016 and March 2022 were collected. Then, we conducted univariate and multivariate Cox analyses to identify independent prognostic parameters to develop the nomogram. The model was evaluated by concordance index (C-index), calibration curve, the area under the curve (AUC), decision curve analysis (DCA), Kaplan-Meier analysis, and subgroup analyses.
Results: Seven variables were selected to construct the nomogram. The results of the C-index (0.783), calibration curve, the AUCs, and subgroup analyses demonstrated the accurate predictive capacity and excellent discriminative ability of the nomogram. The DCA of the model indicated its better clinical net benefit than that of the traditional system.
Conclusion: Evaluation of the predictive performance of the nomogram revealed the superior sensitivity and specificity of the model and the higher prediction accuracy of the outcomes compared with those of the traditional system. The established nomogram may assist patients in consultation and help physicians in clinical decision-making.
(© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Am J Surg Pathol. 2001 Dec;25(12):1501-7. (PMID: 11717539)
Radiol Clin North Am. 2016 May;54(3):553-63. (PMID: 27153788)
N Engl J Med. 2010 Oct 28;363(18):1727-33. (PMID: 20979472)
J Pak Med Assoc. 2021 Oct;71(10):2467-2469. (PMID: 34974596)
Cancers (Basel). 2019 Jul 28;11(8):. (PMID: 31357748)
J Gastrointest Surg. 2021 Mar;25(3):854-855. (PMID: 32632730)
Curr Opin Oncol. 2013 Sep;25(5):571-3. (PMID: 23942303)
J Clin Oncol. 2008 Mar 10;26(8):1364-70. (PMID: 18323559)
Clin Neurol Neurosurg. 2020 Dec;199:106307. (PMID: 33069088)
Am J Surg Pathol. 1997 Apr;21(4):489-96. (PMID: 9130998)
Cancer. 2014 Jun 15;120(12):1763-74. (PMID: 24648013)
J Cancer Res Ther. 2013 Apr-Jun;9(2):284-6. (PMID: 23771376)
J Surg Oncol. 2005 Apr 1;90(1):10-3. (PMID: 15786434)
JAMA Surg. 2019 Mar 1;154(3):e185249. (PMID: 30698615)
Eur J Cancer. 2020 Mar;127:123-129. (PMID: 32007712)
Oncol Lett. 2018 Jun;15(6):9317-9326. (PMID: 29805657)
J Surg Oncol. 2020 Mar;121(4):605-611. (PMID: 32003475)
J Surg Oncol. 2019 Mar;119(4):479-488. (PMID: 30609044)
Chin Med J (Engl). 2007 Mar 5;120(5):363-9. (PMID: 17376304)
J Cancer Res Ther. 2018 Sep;14(Supplement):S796-S799. (PMID: 30249907)
Cancer Metastasis Rev. 2002;21(2):167-83. (PMID: 12465756)
Br J Cancer. 2015 Dec 1;113(11):1602-6. (PMID: 26554650)
Ann Intern Med. 2015 Jan 6;162(1):55-63. (PMID: 25560714)
Oncol Lett. 2018 Sep;16(3):3889-3894. (PMID: 30128003)
Int J Cancer. 2018 Jun 15;142(12):2610-2620. (PMID: 29383713)
J Pediatr Gastroenterol Nutr. 2022 Feb 1;74(2):253-257. (PMID: 34596604)
J Thorac Oncol. 2018 Sep;13(9):1338-1348. (PMID: 29902534)
Pediatr Dev Pathol. 2012;15(1 Suppl):127-80. (PMID: 22420727)
Curr Oncol. 2019 Aug;26(4):e551-e557. (PMID: 31548824)
Neurol India. 2017 Mar-Apr;65(2):408-410. (PMID: 28290416)
Lancet Respir Med. 2018 Jun;6(6):431-441. (PMID: 29669701)
J Clin Oncol. 2013 Mar 20;31(9):1188-95. (PMID: 23358969)
Cancer Med. 2023 Apr;12(8):9260-9271. (PMID: 36951597)
Ann Surg Oncol. 2019 Dec;26(13):4723-4729. (PMID: 31502023)

Keywords: SEER; malignant myofibroblastic tumor; nomogram; overall survival; prognostic model

Date Created: 20230323 Date Completed: 20230510 Latest Revision: 20230511

20240829

PMC10166985

10.1002/cam4.5668

36951597